List of Exelixis Executive and Leadership Team

Leadership Overview

Exelixis has 4 executives leading key functions including finance, clinical development, and operations.

Driven by innovation, Exelixis is dedicated to discovering, developing, and commercializing new medicines for difficult-to-treat cancers, aiming to improve patient outcomes and expand treatment options globally.

Leadership Roles at Exelixis

Chief Financial Officer - Gregorina Parah

Executive Vice President & Chief Financial Officer - Christopher Senner

Senior Vice President, Chief of Staff - Craig Palmer

Head Chief Medical Officer, Clinical Development - Carol O'Hear

Gregorina Parah - Chief Financial Officer

Gregorina Parah, the Chief Financial Officer at Exelixis, directs the company's financial strategy and operations. This leadership role involves managing all aspects of financial planning, accounting, and investor relations, ensuring robust fiscal health for the oncology-focused organization. Parah oversees the allocation of resources to support the discovery, development, and commercialization of new medicines for challenging cancers. The Chief Financial Officer's responsibilities extend to optimizing financial performance and driving sustainable growth, aligning fiscal decisions with the company's mission to bring innovative treatments to patients. Gregorina Parah ensures that financial frameworks effectively support the advancement of Exelixis's drug pipeline and market presence in the United States.

Christopher Senner - Executive Vice President & Chief Financial Officer

Christopher Senner, the Executive Vice President & Chief Financial Officer at Exelixis, guides the company's comprehensive financial architecture and strategic fiscal planning. This executive position encompasses the oversight of all financial reporting, capital management, and the execution of financial strategies that underpin Exelixis's mission in oncology. Senner directs efforts to ensure the financial viability and growth of the organization, supporting the development and commercialization of novel therapeutics for difficult-to-treat cancers. The Executive Vice President & Chief Financial Officer's role is critical in managing investor relations and securing the necessary capital to advance the company's pipeline, including treatments like CABOMETYX and COMETRIQ. Christopher Senner's financial leadership is integral to Exelixis's operational success and its commitment to improving patient lives through innovative medicine.

Craig Palmer - Senior Vice President, Chief of Staff

Craig Palmer, the Senior Vice President, Chief of Staff at Exelixis, provides strategic operational support and drives key initiatives across the organization. This leadership position involves coordinating cross-functional efforts to ensure alignment with the company's overarching goals in oncology drug discovery and development. Palmer facilitates communication and collaboration among executive teams, streamlining processes to enhance efficiency in bringing new medicines to market. The Senior Vice President, Chief of Staff's responsibilities include managing special projects and advising leadership on strategic priorities, directly impacting the company's ability to commercialize treatments for advanced renal cell carcinoma and medullary thyroid cancer. Craig Palmer's role is essential in optimizing operational execution and supporting the strategic direction of Exelixis.

Carol O'Hear - Head Chief Medical Officer, Clinical Development

Carol O'Hear, the Head Chief Medical Officer, Clinical Development at Exelixis, directs the strategic planning and execution of clinical trials for novel oncology therapeutics. This critical role involves overseeing the design and implementation of studies to evaluate the safety and efficacy of new medicines, including those derived from cabozantinib. O'Hear leads the clinical development team, ensuring that all research aligns with regulatory requirements and the company's mission to treat difficult-to-treat cancers. The Head Chief Medical Officer, Clinical Development's responsibilities extend to interpreting clinical data and making key decisions regarding pipeline progression for treatments like CABOMETYX, COMETRIQ, and COTELLIC. Carol O'Hear's medical expertise is fundamental to advancing Exelixis's portfolio and delivering innovative cancer therapies to patients.

Explore Leadership Teams in Manufacturing

Baxter

Baxter International Inc. provides a portfolio of renal and hospital products. The company operates through two segments, Hospital Products and Renal. The Hospital Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies. The Renal segment provides products to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers products for various treatment continuums, such as technologies and therapies for peritoneal dialysis, hemodialysis, continuous renal replacement therapy, and additional dialysis services. The company sells its products for use in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors offices, and by patients at home under physician supervision.

Company Leadership

Merck KGaA

Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA is a multinational pharmaceutical, chemical and life sciences company. Merck operates in Europe, Africa, Asia, Oceania and the Americas. It has major research and development centres in Darmstadt, Boston, Tokyo and Beijing.

Company Leadership

PCI Pharma Servic...

PCI Pharma Services is an integrated full service provider to companies in the global healthcare industry. They offer services including analytical services, formulation development, clinical trial supply, commercial manufacturing and packaging, QP services, supply chain management, storage, and distribution. They are headquartered in Philadelphia, Pennsylvania with locations in the United States and Europe.

Company Leadership

Santen Pharmaceut...

Santen Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries. The company was founded in 1890 by Kenkichi Taguchi, as Taguchi Santendo, and in 1925, Santendo Co., Ltd. was established.

Company Leadership

Frequently Asked Questions Regarding Exelixis Top Executives and Leadership Team

Who leads Exelixis?

Exelixis is led by Gregorina Parah (Chief Financial Officer), along with executives such as Christopher Senner (Executive Vice President & Chief Financial Officer) and Craig Palmer (Senior Vice President, Chief of Staff).

Who is part of Exelixis’s executive team?

The executive team of Exelixis includes leaders such as Gregorina Parah (Chief Financial Officer), Christopher Senner (Executive Vice President & Chief Financial Officer), Craig Palmer (Senior Vice President, Chief of Staff) and other senior executives.

How many executives does Exelixis have?

Exelixis has 4 executives leading key business areas.

What roles are included in Exelixis’s leadership team?

The leadership team of Exelixis includes roles such as Chief Financial Officer, Executive Vice President & Chief Financial Officer, Senior Vice President, Chief of Staff, Head Chief Medical Officer, Clinical Development.